WuXi subsidiary HD to use Irish cell-based assays to monitor Mitochondria

By Dani Bancroft contact

- Last updated on GMT

WuXi's HD to use Irish cell-based assays to monitor Mitochondria

Related tags: Assay

Irish Luxcel will grant access to its consumable in vitro cell toxicity tests to Shanghai-based CRO HD Biosciences to help reduce the risk of post-market drug withdrawal.

Ireland, Cork-based Luxcel Biosciences Ltd. develops assays that can be applied to enzymes, mitochondria, 3D cell-cultures and whole organisms.

One of the applications of MitoXpress is Respirometric Screening Technology (RST), a fluorescence-based assay for high-throughput analysis of oxygen consumption.

In January, HD Biosciences Co., Ltd. (HDB) was acquired​ by one of the major outsourcing competitors in China – WuXi AppTec.

Under the agreement, HD Biosciences will use Luxcel's MitoXpress platform, a plate-based optical sensing assay technology for preclinical safety testing services.

Mitochondrial dysfunction (MD) is a major contributor​ to drug‐induced toxicity, post‐market drug withdrawal, and black box warnings for hepatic and cardiac toxicity.

Richard Fernandes, CEO of Luxcel, told us, MD has risen in priority for many drug developers following the discontinuation of several drugs over recent decades, including cerivastatin, nefazodone and torglitazone.

“So the industry is looking at routinely screening for MD. Apart from their importance in drug toxicity, mitochondria and metabolism are important in the progression of a variety of diseases, such as cancer and diabetes,”​ he added.

“This is so pharma can generate more data that’s more enabling, and why CROs such as HDB are finding MitoXpress appealing,” ​Fernandes added. “Most importantly the MitoXpress kits can be used on fluorescence plate readers – the workhorse of the research laboratory and one of the most prevalent types of assay platforms. Which is why we differ from competitors.”

Manufacturing in Cork

Although the technology application was originally developed with Pfizer Inc., MitoXpress is wholly owned by Luxcel and is now widely used by the industry for ADMET screening​.

Fernandes explained, “The core technology is owned by Luxcel 100%. Pfizer is an important customer of Luxcel, but [the firm] is actually an early adopter of the tech who we worked quite closely with.”

As spin-out of University College Cork (UCC), Fernandes told us Luxcel manufactures all the testing kits at its facilities nearby, and exports them using distribution partners, such as Sapphire for the US, New Zealand and Australia, Amsbio for the UK and Germany and Bio-Gene for Hong Kong and China.

(Feature Image: iStock/eranicle)

Related news

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us


View more